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ABSTRACT 24 
Objective: To assess the efficacy of adalimumab in patients with erosive hand osteoarthritis 25 
(OA).  26 
Method: Patients >50 years old, meeting the ACR criteria for hand OA, with pain >50 on 27 
100mm VAS, morning stiffness >30 minutes and >1 erosive joint on x-ray with synovitis 28 
present on MRI were included in a randomised double-blind placebo-controlled crossover 29 
trial. Patients were randomised to adalimumab (40 mg subcutaneous injections every other 30 
week) or identical placebo injections for 12 weeks followed by an 8-week washout and then 31 
crossed over treatment groups for another 12 weeks. The primary outcome was change in 32 
VAS hand pain over 12 weeks. Secondary outcomes included change in AUSCAN pain, 33 
function and stiffness subscales from baseline to 4, 8 and 12 weeks, change in MRI-detected 34 
synovitis and bone marrow lesions (BMLs) from baseline to 12 weeks and change in VAS 35 
from baseline to 4 and 8 weeks.   36 
Results: We recruited 51 patients and 43 were randomised to either Group 1 (N=18, active 37 
then placebo) or Group 2 (N=25, placebo then active). At 12 weeks there was no difference 38 
between the groups on the primary outcome measure (mean decrease in VAS pain of 3.2mm 39 
(SD 16.7) for adalimumab versus 0.8mm (SD 29.6) for placebo). The adjusted treatment 40 
effect was -0.7mm (95% CI -9.3 to 8.0), P=0.87. No statistically significant differences were 41 
found for any secondary outcomes.  42 
Conclusion: Adalimumab did not show any effect on pain, synovitis or BMLs in patients 43 
with erosive hand OA with MRI-detected synovitis as compared to placebo after 12 weeks.  44 
Clinical trial registration number: ACTRN12612000791831 45 
5 keywords: hand osteoarthritis, synovitis, magnetic resonance imaging, anti-TNF 46 
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INTRODUCTION 48 
 49 
Erosive hand osteoarthritis (OA) is considered a more inflammatory hand OA phenotype1. 50 
Patients are often difficult to treat with a high level of pain and disability. It is characterised 51 
by articular cartilage damage, erosions and remodelling of the subchondral bone2.   52 
 53 
Tumour necrosis factor (TNF) α is a pro-inflammatory cytokine produced by the synovial 54 
cells and chondrocytes and has been implicated in the development and progression of OA3, 4. 55 
This makes TNF α a target for therapy to reduce pain and slow disease progression; however, 56 
there is limited data on the effect of anti-TNF α therapy in patients with hand OA5-8 and 57 
studies to date show mixed findings with regard to clinical and structural progression. In a 58 
randomised, double-blind, placebo-controlled trial over 6 months, Chevalier et al reported 59 
that adalimumab treatment was not superior to placebo to alleviate pain in patients with hand 60 
OA not responding to analgesics and non-steroidal anti-inflammatory drugs (NSAIDS)6. 61 
Another randomised controlled trial (RCT) showed that 1-year of adalimumab treatment did 62 
not reduce symptoms or erosive progression assessed by x-ray5. However, post-hoc findings 63 
from this trial suggested that adalimumab therapy halted erosive progression in a subset of 64 
hand OA patients with clinically swollen joints at baseline5. Therefore, the aim of our study 65 
was to assess the efficacy of adalimumab (Humira, AbbVie Pty Ltd), 40 mg subcutaneous 66 
injections every other week, for 12 weeks in a randomised double-blind placebo-controlled 67 
crossover trial for patients with erosive hand OA and evidence of magnetic resonance 68 
imaging (MRI)-defined synovitis.  69 
 70 
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METHODS 71 
Trial design 72 
This study was a randomised double-blind placebo-controlled crossover trial of adalimumab 73 
versus placebo. In a randomised crossover trial participants are assigned randomly to a 74 
sequence of treatments and each participant serves as his/her own control in estimating 75 
treatment effects9. As a result, fewer patients are required for a crossover trial because it can 76 
achieve the same precision as a parallel group trial with less than half the sample size9.  77 
Settings and locations 78 
Participants were recruited from July 2013 to June 2015 through advertising in local print 79 
media in Hobart, Tasmania, Australia, from the private practice of a study investigator (GJ), 80 
and referrals from other rheumatologists in Hobart. Participants attended clinics at the 81 
Menzies Institute for Medical Research, Hobart, Tasmania.  82 
Participants and Screening Procedure 83 
Participants were first screened over the telephone to determine their interest and initial 84 
eligibility to participate in the trial, after which they were invited to attend the study centre 85 
for a face-to-face screening visit.  Screening and clinical examinations were performed by a 86 
rheumatologist (GJ) and two study nurses (MG and KB).  Participants had a clinical 87 
examination, supplied a blood sample (for a range of laboratory tests, see Supplementary 88 
Table 1), had a chest x-ray (to exclude tuberculosis), a standard AP hand radiograph and a 89 
hand MRI scan. This research was conducted in compliance with the Declaration of Helsinki 90 
and was approved by the Southern Tasmanian Health and Medical Human Research Ethics 91 
Committee. All participants gave informed written consent. 92 
Inclusion and exclusion criteria  93 
We recruited participants aged >50 years, who met the American College of Rheumatology 94 
(ACR) criteria for hand OA10, and had pain >50 on 100mm visual analogue scale (VAS), 95 
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morning stiffness >30 minutes, and >1 erosive joint on x-ray with synovitis present on MRI. 96 
The exclusion criteria are outlined in Supplementary Table 1.  97 
Selection of the index joint 98 
Following a clinical examination, hand x-ray and hand MRI scan, one joint was nominated as 99 
the index joint and this joint was studied throughout the trial. Firstly, clinical examinations 100 
and screening of joint erosion on x-ray was performed by the principal investigator (GJ), who 101 
is a rheumatologist with over 10 years of experience reading X-rays. Patients who had joint 102 
erosion in their clinically eligible joint were then sent for a 1.5T non contrast MRI scan of 103 
their erosive joint to determine whether their erosive hand OA was inflammatory, defined by 104 
the presence of synovitis on MRI. If >1 erosive joints were identified during initital screening 105 
the most painful joint was used. Screening for the presence of synovitis was undertaken by an 106 
experienced MRI reader (PB), a member of the Outcome Measures in Rheumatology 107 
(OMERACT) MRI Inflammatory arthritis group, and co-author of the OMERACT hand OA 108 
MRI score (HOAMRIS)11. 109 
Interventions 110 
Patients were randomised to adalimumab (40 mg subcutaneous injections every other week) 111 
or placebo for 12 weeks (treatment period 1) followed by an 8-week washout and then the 112 
converse treatment for 12 weeks (treatment period 2) (Figure 1).  113 
Outcomes 114 
The primary outcome was change in VAS hand pain over 12 weeks. Secondary outcomes 115 
included change in the AUSCAN pain, function and stiffness subscale from baseline to 4, 8 116 
and 12 weeks, improvement in MRI-detected synovitis and BMLs from baseline to 12 weeks 117 
and change in the VAS pain subscale from baseline to 4 and 8 weeks. 118 
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Outcome measures 119 
Pain, function and stiffness 120 
Hand pain was measured using a 100mm VAS by asking “on this line, where would you rate 121 
your pain, using the last 7 days as a timeframe?” Hand pain, function and stiffness were 122 
measured using the Australian/Canadian Hand OA Index (AUSCAN)12 on eight occasions 123 
(baseline, 4, 8 and 12 weeks of each treatment period), using the last 48h as a timeframe. 124 
AUSCAN contains five items referring to hand pain, nine items relating to difficulty with 125 
hand functions and one question on severity of morning stiffness. The questions were scaled 126 
on a 100 mm VAS. Total pain, function and stiffness subscale scores were calculated by 127 
adding each of the items together. The possible range of scores was 0–500 for pain, 0–900 for 128 
function and 0–100 for stiffness. 129 
MRI measures 130 
Images of the index joint were acquired at baseline and 12 weeks of each treatment period 131 
with a 1.5T whole-body magnetic resonance unit (Siemens, Espree) using five sequences 132 
(Supplementary Table 2). One reader (IKH) read the baseline and 12 week MRIs with known 133 
time sequence for each treatment period (blinded to treatment allocation). Synovitis and 134 
BMLs were scored according to the OMERACT HOAMRIS11 or the OMERACT thumb base 135 
OA MRI scoring system (TOMS)13. The reliability of these scoring systems, as previously 136 
published, shows good to very good ICC values11, 13. Synovitis was assessed without the use 137 
of gadolinium contrast. Thickened synovium were scored: 0=Normal, 1=Mild, 2=Moderate, 138 
3=Severe. The 1-3 scores are defined by thirds of the presumed maximum volume of the 139 
synovial compartment. BMLs were defined as a signal characteristic consistent with 140 
increased water content and with ill-defined margins within the trabecular bone and were 141 
scored as follows: 0=Normal, 1=Mild: 1-33% of bone volume, 2=Moderate: 34-66% of bone 142 
volume, 3=Severe: 67-100% of bone volume; where “bone volume” refers to the proximal 143 
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and distal part of the joint combined. Changes in synovitis and BMLs over 12 weeks were 144 
documented in 0.5 increments in case changes in these features were present, but were not 145 
enough to be scored within the next category. This is standard practice for performing 146 
longitudinal measurements using these scoring systems11, 13. Improvement in synovitis or 147 
BMLs in the index joint was defined as a decrease by 0.5 or more over the treatment period. 148 
What level reflects clinical significance is uncertain and has not yet been studied.  149 
Concomitant medication/analgesic use 150 
To maintain the pragmatic nature of the trial, there were no restrictions with regard to 151 
concomitant analgesic medications (including corticosteroids). All participants were allowed 152 
to continue taking the medications that they were taking at their screening visit for the 153 
duration of the trial. Participants were asked to keep medications as stable as possible but if a 154 
participant experienced an increase in pain requiring an increase in the dose of analgesics the 155 
reason for the dose increase and the dose used was documented. Medication usage was 156 
recorded at baseline, 4, 8 and 12 weeks of each treatment period.  157 
Safety 158 
Adverse events were defined as any untoward event occurring during the trial regardless of 159 
whether it was considered medication-related. Serious adverse events were defined as 160 
unplanned hospital admissions, new cancer diagnoses or death during the study.   161 
Sample size 162 
The power calculations were conducted considering the cross-over trial design, where each 163 
participant experiences both treatments assigned in random order. Enrolling a total of 40 164 
patients gave us 97% power, and 5% probability of type 1 error (alpha=0.05) to detect a 165 
15mm difference between adalimumab and placebo on the VAS scale (SD of pain change 166 
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23.8mm, based on in-house data14). We assumed a correlation of 0.5 between readings made 167 
on the same person.  168 
Randomisation and sequence generation 169 
Participants were allocated to either placebo or adalimumab at a ratio of 1:1 based on 170 
computer-generated random numbers. The random allocation sequence was automatically 171 
generated, and a security protected central automated allocation procedure was used to 172 
allocate participants to treatment arms. This was then used by one author (LL) who had no 173 
contact with participants to dispense the syringes of allocated medication. Research nurses 174 
enrolled participants in the trial, and then gave the allocated medication to each individual 175 
patient. The active treatment and placebo product were visually identical.  Participants and 176 
staff involved in patient care remained blinded to treatment allocation throughout the trial. 177 
Statistical methods 178 
We used Stata 12.0 (StataCorp LP) for statistical analyses. Statistical significance was set as a 179 
P value <0.05. Analysis was by intention to treat (ITT) as randomised in those receiving at 180 
least one dose of the intervention in both treatment periods of the study. Change in each 181 
outcome was assessed using the difference between the factor at baseline and each study visit 182 
(4, 8 and 12 weeks). Baseline values were considered week 0 of treatment period 1 or 2 (see 183 
Figure 1), as recommended for crossover trials9, 15. The primary outcome was change over 12 184 
weeks as assessed by the VAS pain scale. 185 
For continuous outcomes, including change in VAS, AUSCAN pain, function and stiffness 186 
subscales, treatment effects were calculated using a repeated measures modelling approach 187 
adjusting for the difference in each participants baseline value during treatment period 1 and 188 
period 2 (i.e. adjusting for within-subject baseline difference, method IV as recommended in 189 
Mehrotra16). Data was checked for normality and for homogeneity of variance. For 190 
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categorical outcomes, including improvement in synovitis and BMLs, χ2 tests were used to 191 
examine differences in the proportion of participants improving during each treatment period. 192 
We then used log-binomial generalised estimating equations (GEE) analysis to explore the 193 
risk of having an improvement in synovitis or BML score in the active versus placebo groups. 194 
In all methods we clustered on participant ID, and adjusted for the order in which the 195 
participant received their treatment (e.g. Active then placebo, or Placebo then active).  196 
χ2 tests were used to compare numbers of adverse events.  197 
There was a discordance between the investigator who screened the study patients for 198 
synovitis at enrollment and the scoring of synovitis at the completion of the study. This 199 
resulted in four study patients in the trial who did not have synovitis according to 200 
HOAMRIS11 and/or TOMS13 scoring system. Analyses were repeated with these four study 201 
participants excluded.   202 
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RESULTS 203 
Study participants 204 
In total 51 participants attended screening for the study, of whom 8 were excluded (Figure 1). 205 
The remaining 43 participants were randomised to receive either adalimumab (n=18) or 206 
placebo (n=25) over treatment period 1. There were 5 study participants that either withdrew 207 
during the study, or had missing primary outcome data at 12 weeks.  208 
Table 1 shows the baseline characteristics of study participants by treatment received during 209 
treatment period 1. At baseline, participants (n=43) had a mean age of 61 years (SD 8.4), 210 
mean BMI of 28.9 (SD 4.2), mean VAS pain level of 63.6 (SD 17.7) out of 100 (indicating 211 
highly symptomatic disease), and 77% were women. There were five study participants that 212 
were enrolled based on the presence of erosive OA in the first carpometacarpal 213 
(CMC1) joint. The remaining participants had erosive OA in an interphalangeal joint.   214 
Outcomes 215 
Data on the main outcomes are shown in Figure 2 and Tables 2-5.   216 
Primary outcome 217 
At 12 weeks there was no difference in change of VAS pain between the groups (Table 3). 218 
Mean decrease in VAS pain was 3.2mm (SD 16.7) following adalimumab treatment versus 219 
0.8mm (SD 29.6) following placebo treatment. The adjusted treatment effect was -0.7mm 220 
(95% CI -9.3 to 8.0), P=0.87). During treatment period 1, the adalimumab treated group had a 221 
decrease in pain of 1.9mm (Table 2 and Figure 2). This group had an increase in pain of 222 
5.1mm when they received placebo during treatment period 2.  During treatment period 1, the 223 
placebo treated group had a decrease in pain of 5.0mm. This group also had a decrease in 224 
pain of 4.2mm when they received adalimumab during treatment period 2.  These changes are 225 
small and are not considered clinically important.  226 
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Secondary outcomes 227 
No statistically significant differences between adalimumab treatment versus placebo 228 
treatment was seen for any secondary symptomatic outcomes (Table 3). There were small 229 
changes in synovitis and BML scores in both groups and no significant difference between 230 
the groups was observed (12% had an improvement in synovitis score with adalimumab vs 231 
10% with placebo (P=0.63); 5% had an improvement in BML score with adaliumumab vs 7% 232 
with placebo (P=0.67) (Tables 4-5)). 233 
The results for the primary and secondary outcomes were unchanged when the four patients 234 
without synovitis according to the HOAMRIS11 and/or TOMS13 scoring system were 235 
excluded. The results were also unchanged when the five patients with erosive OA in their 236 
CMC1 joint were excluded. Analgesic use throughout both treatment periods was similar 237 
between groups (data not shown).  238 
Adverse events 239 
Adverse events were common, with 55% (n=23) of the placebo group and 36% (n=15) of the 240 
active group experiencing at least one adverse event (Table 6). Differences in the total 241 
number of adverse events and prevalence of events were not statistically significant. One 242 
participant had a serious adverse event with a non-elective hospitalization for treatment of 243 
cellulitis after cutting his/her finger whilst in the adalimumab arm. Cellulitis was possibly 244 
causally related to the study drug. 245 
 246 
  247 
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DISCUSSION 248 
 249 
This RCT demonstrated that 12 weeks of treatment with adalimumab (40 mg subcutaneous 250 
injections every other week) was no different to placebo to alleviate pain, synovitis or BMLs 251 
in patients with erosive hand OA presenting with synovitis on MRI. The main clinical 252 
outcome (change over 12 weeks as assessed by VAS pain) was not different between the 253 
adalimumab and placebo groups. Furthermore, no clinically or statistically significant 254 
differences were found for any of the secondary outcomes including patient-reported 255 
outcomes and MRI-assessed structural abnormalities (synovitis and BMLs). The results 256 
suggest that pain and inflammation are not responsive to TNF α inhibition in this patient 257 
population.  258 
 259 
Anti-TNF α therapies have been very successful for treating pain and structural disease 260 
progression in inflammatory arthritis such as RA17. There is limited data on the effect of anti-261 
TNF α therapy in patients with hand OA5-8 and studies to date show mixed findings with 262 
regard to clinical and structural progression. Evidence from trial data has consistently shown 263 
that anti-TNF α therapy does not improve symptoms in hand OA patients5-7 and the findings 264 
from our study support this. In a randomised, double-blind, placebo-controlled trial over 6 265 
months, Chevalier et al reported that adalimumab was not superior to placebo to alleviate 266 
pain in patients with hand OA not responding to analgesics and NSAIDS6. Similarly 267 
Verbruggen et al showed that 1-year of adalimumab treatment did not reduce symptoms 268 
including pain, stiffness, function and number of tender joints5. 269 
 270 
Despite these previous negative trial findings, we hypothesised that adalimumab may be 271 
effective in erosive hand OA when inflammation was present (assessed in our study as MRI-272 
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detected synovitis), given TNF α’s pro-inflammatory role in the synovial membrane18. In 273 
support of this, a previous study by Verbruggen et al suggested that adalimumab could halt 274 
erosive progression on x-ray in a subset of patients with clinically swollen joints at baseline5. 275 
However, despite selecting a sub-group of erosive hand OA patients with synovitis, our trial 276 
failed to show an effect for pain or structure (assessed as synovitis and BMLs on MRI as 277 
secondary outcomes). The failure of adalimumab in painful hand OA may indicate that TNF 278 
α may not be the right treatment target, even in those with definite synovitis. Unlike RA, 279 
inflammation in OA may be present as a result of joint damage as opposed to primary 280 
immune activation. It may not be driving the disease but rather represent a consequence of 281 
the disease process. However, in contrast to this theory, several studies have shown that 282 
synovitis on both MRI19 and ultrasound20 as well as clinical signs of inflammation21 predict 283 
future structural progression. Whether other features that are co-occurring with synovitis are 284 
of larger importance than the synovitis itself, should be further explored. 285 
 286 
A treatment for erosive hand OA would need to improve symptoms in order for it to be 287 
successful. Our study duration of 12 weeks to assess the effect on pain is sufficient, as 288 
symptom modification should ideally be achieved by this time, otherwise patients would not 289 
be motivated to continue treatment. Anti-TNF α therapy in inflammatory arthritis such as 290 
PsA, RA and ankylosing spondylitis is associated with a rapid pain response (starting as early 291 
as 2-4 weeks and reaching maximum efficiency by 8-12 weeks)17. It is possible that anti-TNF 292 
α therapy may exert differential effects on pain and structure. Our 12 week study may not 293 
have been long enough to see structure modification. Furthermore, our crossover study design 294 
was not the ideal design to examine changes in structure. The structural/imaging outcomes in 295 
our study were synovitis and BMLs which likely reflect inflammation. Over 12 weeks we 296 
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found only small changes in synovitis and BML scores and no difference between the 297 
treatment versus placebo groups. A successful therapy for erosive hand OA would ideally 298 
slow or prevent the destructive subchondral remodeling that occurs in this disease. Erosions 299 
and inflammation may represent different pathological processes22.  300 
 301 
Hand OA trials have shown to have high placebo effects23, and this was also the case in the 302 
previous studies that trialled adalimumab for hand OA6, 7. In our trial we did not see large 303 
effects from placebo, in fact, pain improvement in the VAS and AUSCAN pain scales was 304 
well below the level of clinical relevance in both the adalimumab and placebo groups. This 305 
could be due to the crossover study design, as crossover trials are less prone to placebo 306 
effects24.   307 
 308 
Advantages of a crossover study design include smaller sample sizes over parallel designs, 309 
the elimination of between subject variability as each participant serves as his/her own 310 
control and enhanced recruitment as potential participants are aware they will receive the 311 
active treatment at some point. However, there are some considerations to this study design 312 
that need to be discussed. Firstly, as outlined above, crossover study designs are not ideal to 313 
examine structural modification. Secondly, crossover studies can be limited because 314 
treatment from the first period may have a carryover effect9. To mitigate against this, we had 315 
an 8-week washout, in which the treatment could ‘wear off’ before the participant started the 316 
next treatment period. The average half-life of adalimumab is 2 weeks, ranging between 10 to 317 
20 days17. While the optimal length of a washout period is unclear, for a drug trial it is 318 
suggested to be between 3-5 times the half-life of a drug. This would suggest that our 319 
washout period was reasonable. Furthermore, our data do not show any carryover effects as 320 
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there was very little improvement in pain, regardless of the order they received the 321 
treatments. As recommended9, 15, our analysis accommodated the paired nature of the design 322 
and we reported our data in a manner that facilitates understanding of any carryover effects 323 
and missing data. Furthermore, the continuous outcomes were adjusted for the difference in 324 
each participants baseline value during treatment period 1 and period 2 (i.e. adjusted for 325 
within-subject baseline difference, method IV as recommended in Mehrotra16).  326 
 327 
There are potential limitations to this study. First, synovitis was assessed without the use of 328 
gadolinium contrast, which may be less sensitive to detect changes in synovitis. Also, 329 
synovitis was moderate at baseline and the level of inflammation may have been too low to 330 
detect meaningful changes. Second, following a clinical examination, x-ray and MRI scan, 331 
one joint was nominated as the index joint and this joint was studied throughout the trial. We 332 
did not collect information about the number of other hand joints involved (including the 333 
presence of tender or swollen joints) and improvements may have occurred in these joints. 334 
Similarly the MRI scans were only taken of the index joint therefore we could not assess MRI 335 
changes in the other hand joints. Furthermore, we included patients with both interphalangeal 336 
and thumb base OA. It has been proposed that thumb base OA may be a unique phenotype. 337 
We did perform a sensitivity analysis, excluding the five patients that were included based on 338 
erosive CMC1 OA in their index joint, and our results were unchanged. However, as we did 339 
not collect information about other hand joints, we are unable to say how many of our 340 
patients in total had CMC1 involvement. Third, hand x-rays were performed for screening 341 
purposes only, and were not scored to define disease severity in these patients. Therefore the 342 
level of disease severity and phase of erosion damage25 was not quantified and could not be 343 
Page 16 
© 2018. This manuscript version is made available under the CC-BY-NC-ND 4.0 
license http://creativecommons.org/licenses/by-nc-nd/4.0/ 
https://doi.org/10.1016/j.joca.2018.02.899  
 
examined in exploratory analysis. Screening of erosions was performed by the principal 344 
investigator (GJ), who is a rheumatologist with over 10 years of experience reading X-rays.  345 
 346 
CONCLUSIONS  347 
Adalimumab did not show any effect on pain, synovitis or BMLs in patients with erosive 348 
hand OA with MRI-detected synovitis, as compared to placebo after 12 weeks treatment. 349 
This suggests that pain and inflammation are not responsive to TNF α inhibition in this 350 
patient population. 351 
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Figure legends and Tables 
Figure 1: Study flow chart 
Figure 2: Mean VAS pain score ± standard error over each 12 week treatment period. 
  
Page 18 
© 2018. This manuscript version is made available under the CC-BY-NC-ND 4.0 
license http://creativecommons.org/licenses/by-nc-nd/4.0/ 
https://doi.org/10.1016/j.joca.2018.02.899  
 
 
 
Table 1:  Baseline characteristics of study participants, by treatment received during 
treatment period 1 
 Baseline characteristics N Adalimumab N Placebo 
  Mean (SD)  Mean (SD) 
Age, years 18 63.1 (8.4) 25 61.2 (8.4) 
Women, n (%) 18 15 (83) 25 18 (72) 
Weight, kg 18 77.3 (12.9) 25 79.3 (15.0) 
Height, cm 18 162.7 (8.7) 25 166.0 (8.3) 
Body Mass Index, kg/m2 18 29.2 (3.8) 25 28.7 (4.5) 
VAS pain score (0-100 mm) 18 63.9 (17.1) 25 63.4 (18.5) 
AUSCAN pain subscale score (0-500) 18 332 (98.5) 25 308.4 (96.4) 
AUSCAN function subscale score (0-900) 18 622.5 (181.9) 25 559.8 (165.6) 
AUSCAN stiffness subscale score (0-100) 18 73.7 (21.3) 25 66.9 (17.0) 
Medication use     
    Paracetamol, n (%) 18 7 (39) 25 13 (52) 
    Average paracetamol dose, mg 7 1588 (1168) 13 1387 (954) 
    COX-2 inhibitors, n (%) 18 1 (6) 25 4 (16) 
    NSAIDS, n (%) 18 7 (39) 25 11 (44) 
Number of pain medicines, n (%)     
    0  5 (28)  6 (24) 
    1  6 (33)  6 (24) 
    2  6 (33)  9 (36) 
    3  1 (6)  3 (12) 
    4  0  1 (4) 
Synovitis (0-3) 18 1.3 (0.6) 24 1.2 (0.8) 
Bone marrow lesions (BMLs) (0-3) 18 1.0 (0.8) 25 1.3 (0.7) 
AUSCAN - Australian/Canadian Hand OA Index, VAS - Visual Analogue Scale, COX-2 -  
Cyclooxygenase-2, NSAIDS - Non-steroidal anti-inflammatory drugs. 
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Table 2: Change in primary outcome (VAS pain score from baseline to 12 weeks) over 
the two treatment periods, based on the order in which they received the treatment 
  
Treatment period 
 Within-individual 
difference:  
Active-placebo 
Treatment sequence 1 2   
Active then placebo     
Mean (SE) -1.9 (3.4) 5.1 (8.5)  -7.1 (8.6) 
N 18 16  16 
     
Placebo then active     
Mean (SE) -5.0 (5.5) -4.2 (3.9)  1.2 (6.1) 
N 23 23  22 
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Table 3: Change in secondary outcomes by treatment group, and the adjusted treatment effect 
 N Placebo 
Mean change (SD) 
N Active 
Mean change (SD) 
N Adjusted treatment effect* 
Mean difference (95% CI) 
P-value 
Primary outcome        
Change in VAS pain        
   Baseline to 12 weeks 39 -0.8 (29.6) 41 -3.2 (16.7) 41 -0.7 (-9.3 to 8.0) 0.87 
        
Secondary outcomes        
Change in VAS pain        
   Baseline to 4 weeks 41 -4.1 (23.0) 40 -6.1 (22.7) 41 -0.2 (-8.1 to 7.6) 0.95 
   Baseline to 8 weeks 39 -5.2 (27.4) 41 -7.7 (21.5) 41 -0.4 (-10.2 to 9.4) 0.94 
        
Change in AUSCAN pain        
   Baseline to 4 weeks 42 -12.9 (132.2) 41 -31.0 (102.4) 41 -1.9 (-40.7 to 36.9) 0.92 
   Baseline to 8 weeks 41 -18.7 (140.9) 41 -41.5 (97.2) 41 -4.3 (-52.7 to 44.1) 0.86 
   Baseline to 12 weeks 40 -4.9 (142.6) 41 -20.9 (83.7) 41 8.7 (-34.0 to 51.4) 0.68 
        
Change in AUSCAN function        
   Baseline to 4 weeks 41 -23.0 (169.5) 40 -21.9 (166.7) 41 23.2 (-34.1 to 80.5) 0.42 
   Baseline to 8 weeks 41 -8.0 (198.7) 41 -61.4 (189.0) 41 -19.4 (-103.1 to 64.4) 0.64 
   Baseline to 12 weeks 40 -6.7 (215.8) 41 -23.0 (136.9) 41 18.5 (-46.4 to 83.5) 0.57 
        
Change in AUSCAN stiffness        
   Baseline to 4 weeks 42 -4.9 (25.7) 41 -4.1 (23.2) 41 1.0 (-8.7 to 10.7) 0.84 
   Baseline to 8 weeks 40 -7.5 (25.9) 41 -4.3 (21.4) 41 4.9 (-6.6 to 16.3) 0.39 
   Baseline to 12 weeks 40 -5.3 (28.8) 41 -2.9 (22.4) 41 3.3 (-5.5 to 12.1) 0.45 
*The treatment effect was adjusted for within-subject baseline difference and the order in which the participant received their treatment (e.g. Active then 
placebo, or Placebo then active).  VAS - Visual Analogue Scale, range: 0 – 100; AUSCAN - Australian/Canadian Hand OA Index pain range: 0 – 500; 
AUSCAN - Australian/Canadian Hand OA Index function range: 0 – 900; AUSCAN - Australian/Canadian Hand OA Index stiffness range: 0 – 100; CI – 
confidence interval 
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Table 4: Proportion of participants with an improvement in synovitis score from 
baseline to 12 weeks, the estimated treatment effect, and the proportion of 
participants with an improvement based on the order in which they received the 
treatment 
  Treatment effect   
Active, Improved n (%) 5 (12%)   
N  42   
     
Placebo, Improved n (%) 4 (10%)   
N  41   
     
Treatment effect*     
Relative risk  1.2   
95% CI  0.3 to 4.6   
P-Value  P=0.74   
  
Treatment period 
 χ2 P-Value for 
difference 
Treatment sequence 1 2   
Active then placebo     
Improved, n (%) 2 (11%) 0 (0%)  N/A 
N 18 17   
     
Placebo then active     
Improved, n (%) 4 (17%) 3 (13%)  P=0.41 
N 24 24   
*The treatment effect was adjusted for the order in which the participant received their 
treatment (e.g. Active then placebo, or Placebo then active).   
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Table 5: Proportion of participants with an improvement in bone marrow lesion 
(BML) score from baseline to 12 weeks, the estimated treatment effect, and the 
proportion of participants with an improvement based on the order in which they 
received the treatment 
  Treatment effect   
Active, Improved n (%) 2 (5%)   
N  42   
     
Placebo, Improved n (%) 3 (7%)   
N  41   
     
Treatment effect*     
Relative risk  0.7   
95% CI  0.1 to 4.0   
P-Value  0.65   
  
Treatment period 
 χ2 P-Value for 
difference 
Treatment sequence 1 2   
Active then placebo     
Improved, n (%) 0 (0%) 0 (0%)  N/A 
N 18 17   
     
Placebo then active     
Improved, n (%) 3 (13%) 2 (8%)  0.58 
N 24 24   
*The treatment effect was adjusted for the order in which the participant received their 
treatment (e.g. Active then placebo, or Placebo then active).   
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Table 6: Prevalence and number of adverse events, by treatment received 
 Placebo 
N=42 
Active 
N=42 
Adverse events   
Prevalence of at least one adverse event (n, %) 23 (54.8) 15 (35.7) 
   
Total number of adverse events 32 27 
   
Prevalence of (n, %):   
   Fall  0  2 (4.8) 
   Headache 5 (11.9) 3 (7.1) 
   Other joint pain 6 (14.3) 2 (4.8) 
   Insomnia 1 (2.4) 0 
   Upper respiratory tract infection 5 (11.9) 1 (2.4) 
   Sinusitis 2 (4.8) 1 (2.4) 
   Vertigo 0 2 (4.8) 
   Eczema 1 (2.4) 0 
   Increased hand pain/swelling 1 (2.4) 2 (4.8) 
   Sore eyes 2 (4.8) 0 
   Mouth ulcers  2 (4.8) 0 
   Nausea/vomiting   1 (2.4) 2 (4.8) 
   Fatigue  1 (2.4) 0 
   Hashimoto’s disease   0 1 (2.4) 
   Hypertension  0 1 (2.4) 
   Rhinitis 0 1 (2.4) 
   Urinary tract infection  1 (2.4) 1 (2.4) 
   Reaction at site 0 3 (7.1) 
   Rash or itching 2 (4.8) 2 (4.8) 
   Shortness of breath 1 (2.4) 0 
   Shingles  0 1 (2.4) 
   Cataract Removal  1 (2.4) 0 
   Gastroscopy 0 1 (2.4) 
   Cellulitis 0 1 (2.4) 
   
Serious adverse events   
   Number of non-elective hospital admissions 0 1 
   Death 0 0 
   Cancer 0 0 
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